Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression.
We report a 35-year-old female receiving natalizumab as monotherapy for multiple sclerosis who subsequently developed severe cytomegalovirus gastritis. As cytomegalovirus gastritis has not been previously described during natalizumab treatment, we discuss the biological plausibility of this potential association and avenues for further study.
Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO.
Stephen P
SP
Persaud
Combined BA/MD Program, University of Missouri-Kansas City School of Medicine, Kansas City, MO.
Adil
A
Hassan
Department of Pathology and Immunology, Division of Anatomic and Molecular Pathology, Washington University School of Medicine, St. Louis, MO.
Anjum
A
Hassan
Endoscopy and Colonoscopy Center, Hazelwood, MO.
Tariq
T
Hassan